Comparative Pharmacology
Head-to-head clinical analysis: ADZENYS ER versus EVEKEO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADZENYS ER versus EVEKEO.
ADZENYS ER vs EVEKEO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
None Documented
None Documented
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Category C
Category C
CNS Stimulant
CNS Stimulant